Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
20,761,963
-
Number of holders
-
22
-
Total 13F shares, excl. options
-
2,658,168
-
Shares change
-
+6,120
-
Total reported value, excl. options
-
$7,523,090
-
Value change
-
-$53,802
-
Number of buys
-
3
-
Number of sells
-
-8
-
Price
-
$2.83
Significant Holders of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) as of Q4 2024
26 filings reported holding CASI - CASI Pharmaceuticals, Inc. - Ordinary Shares as of Q4 2024.
CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) has 22 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,658,168 shares
of 20,761,963 outstanding shares and own 13% of the company stock.
Largest 10 shareholders include Foresite Capital Management VI LLC (1,329,383 shares), VR Adviser, LLC (987,259 shares), Woodline Partners LP (99,690 shares), Wellington Shields Capital Management, LLC (85,835 shares), ADAR1 Capital Management, LLC (46,320 shares), RENAISSANCE TECHNOLOGIES LLC (39,400 shares), Wellington Shields & Co., LLC (30,091 shares), GEODE CAPITAL MANAGEMENT, LLC (19,363 shares), UBS Group AG (11,308 shares), and Royal Bank of Canada (6,900 shares).
This table shows the top 22 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.